Press coverage about Ardelyx (NASDAQ:ARDX) has trended somewhat negative on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ardelyx earned a media sentiment score of -0.22 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the next few days.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Ardelyx from a “hold” rating to a “sell” rating in a report on Tuesday, April 25th. Citigroup Inc. reiterated a “buy” rating and set a $12.00 price objective (down previously from $17.00) on shares of Ardelyx in a report on Monday, May 15th. Cantor Fitzgerald reiterated an “overweight” rating and set a $12.00 price objective (down previously from $19.00) on shares of Ardelyx in a report on Friday, May 19th. ValuEngine lowered shares of Ardelyx from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, BTIG Research dropped their price objective on shares of Ardelyx from $18.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday, May 23rd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $14.13.
Shares of Ardelyx (NASDAQ:ARDX) opened at 5.30 on Friday. The firm’s market cap is $251.15 million. The company has a 50 day moving average of $6.96 and a 200-day moving average of $11.68. Ardelyx has a 12-month low of $4.05 and a 12-month high of $16.30.
Ardelyx (NASDAQ:ARDX) last issued its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.06. Analysts predict that Ardelyx will post ($2.46) EPS for the current year.
Ardelyx Company Profile
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc and related companies with MarketBeat.com's FREE daily email newsletter.